Rauch, Daniel A.
Olson, Sydney L.
Harding, John C.
Sundaramoorthi, Hemalatha
Kim, Youngsoo
Zhou, Tianyuan
MacLeod, A. Robert
Challen, Grant
Ratner, Lee http://orcid.org/0000-0003-2744-7294
Funding for this research was provided by:
National Cancer Institute (CA100730, CA063417, CA234640)
Alvin J. Siteman Cancer Center
National Institute of Allergy and Infectious Diseases (26652)
Article History
Received: 3 July 2020
Accepted: 17 August 2020
First Online: 28 August 2020
Ethics approval and consent to participate
: Animal experiments were carried out in a humane fashion and approved by the Institutional Animal Care and Use Committee (IACUC; Animal Welfare Assurance # A-3381–01).
: Not applicable.
: Drs Kim, Zhou, and MacLeod are employed by Ionis Pharmaceuticals who have manufactured the IRF4 ASOs and have ongoing clinical trials with these reagents. Other authors have no funding, honoraria, and stock interests to disclose.